Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1040

1.

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.

Arun B, Akar U, Gutierrez-Barrera AM, Hortobagyi GN, Ozpolat B.

Int J Oncol. 2015 Jul;47(1):262-8. doi: 10.3892/ijo.2015.3003. Epub 2015 May 12.

PMID:
25975349
2.

Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment.

Sevcikova K, Zhuang Z, Garcia-Manero G, Alvarez RH, Kantarjian HM, Mego M, Albarracin C, Tang G, Strom SS, Medeiros LJ, Hortobagyi GN, Reuben JM, Khoury JD.

Leukemia. 2015 May 15. doi: 10.1038/leu.2015.122. [Epub ahead of print] No abstract available.

PMID:
25975189
3.

Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer.

Chavez-MacGregor M, Niu J, Zhang N, Elting LS, Smith BD, Banchs J, Hortobagyi GN, Giordano SH.

J Clin Oncol. 2015 Jul 1;33(19):2176-83. doi: 10.1200/JCO.2014.58.9465. Epub 2015 May 11.

PMID:
25964256
4.

BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.

Mitri ZI, Jackson M, Garby C, Song J, Giordano SH, Hortobágyi GN, Singletary CN, Hashmi SS, Arun BK, Litton JK.

Oncologist. 2015 Jun;20(6):593-7. doi: 10.1634/theoncologist.2014-0425. Epub 2015 May 6.

PMID:
25948675
5.

Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.

Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F.

Clin Breast Cancer. 2015 Mar 24. pii: S1526-8209(15)00068-3. doi: 10.1016/j.clbc.2015.03.004. [Epub ahead of print]

PMID:
25913905
6.

Reply to f.-C. Bidard et Al.

Smerage JB, Barlow WE, Hortobagyi GN, Hayes DF.

J Clin Oncol. 2015 May 10;33(14):1623. doi: 10.1200/JCO.2014.60.5519. Epub 2015 Apr 13. No abstract available.

PMID:
25870090
7.

Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2.

Hortobagyi GN.

Neoplasia. 2015 Mar;17(3):279-88. doi: 10.1016/j.neo.2015.01.005. Review.

8.

Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer.

Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT.

J Cancer. 2015 Jan 22;6(4):310-8. doi: 10.7150/jca.10580. eCollection 2015.

9.

Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer.

Greenlee H, Balneaves LG, Carlson LE, Cohen M, Deng G, Hershman D, Mumber M, Perlmutter J, Seely D, Sen A, Zick SM, Tripathy D; Society for Integrative Oncology Guidelines Working Group.

J Natl Cancer Inst Monogr. 2014 Nov;2014(50):346-58. doi: 10.1093/jncimonographs/lgu041.

PMID:
25749602
10.

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230 Investigators.

N Engl J Med. 2015 Mar 5;372(10):923-32. doi: 10.1056/NEJMoa1413204.

PMID:
25738668
11.

Functional consequence of the MET-T1010I polymorphism in breast cancer.

Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM.

Oncotarget. 2015 Feb 20;6(5):2604-14.

12.

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.

Gonzalez-Angulo AM, Parinyanitikul N, Lei X, Mittendorf EA, Zhang H, Valero V, Hunt KK, Hortobagyi GN, Chavez-MacGregor M.

Br J Cancer. 2015 Feb 17;112(4):630-5. doi: 10.1038/bjc.2014.647. Epub 2015 Jan 13.

PMID:
25584488
13.

Circulating tumor cells in newly diagnosed inflammatory breast cancer.

Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, Andreopoulou E, Alvarez RH, Woodward WA, Hortobagyi GN, Cristofanilli M, Reuben JM.

Breast Cancer Res. 2015 Jan 9;17:2. doi: 10.1186/s13058-014-0507-6.

14.

Outcomes of children exposed in utero to chemotherapy for breast cancer.

Murthy RK, Theriault RL, Barnett CM, Hodge S, Ramirez MM, Milbourne A, Rimes SA, Hortobagyi GN, Valero V, Litton JK.

Breast Cancer Res. 2014 Dec 30;16(6):500. doi: 10.1186/s13058-014-0500-0.

15.

Adjuvant ovarian suppression in premenopausal breast cancer.

Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; SOFT Investigators; International Breast Cancer Study Group.

N Engl J Med. 2015 Jan 29;372(5):436-46. doi: 10.1056/NEJMoa1412379. Epub 2014 Dec 11.

PMID:
25495490
16.

Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes.

Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM.

Clin Breast Cancer. 2015 Apr;15(2):153-60. doi: 10.1016/j.clbc.2014.09.006. Epub 2014 Oct 2.

PMID:
25454687
17.

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN.

J Clin Oncol. 2015 Jan 1;33(1):58-64. doi: 10.1200/JCO.2014.56.3296. Epub 2014 Nov 24.

PMID:
25422488
18.

Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer.

Mego M, Zuo Z, Gao H, Cohen EN, Giordano A, Tin S, Anfossi S, Jackson S, Woodward W, Ueno NT, Valero V, Alvarez RH, Hortobagyi GN, Khoury JD, Cristofanilli M, Reuben JM.

Thromb Haemost. 2015 Mar;113(3):593-8. doi: 10.1160/TH14-07-0597. Epub 2014 Nov 6.

PMID:
25373787
19.

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer.

Sohn J, Liu S, Parinyanitikul N, Lee J, Hortobagyi GN, Mills GB, Ueno NT, Gonzalez-Angulo AM.

J Cancer. 2014 Oct 15;5(9):745-53. doi: 10.7150/jca.9696. eCollection 2014.

20.

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA 3rd, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J.

Ann Oncol. 2014 Dec;25(12):2357-62. doi: 10.1093/annonc/mdu456. Epub 2014 Sep 17.

PMID:
25231953
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk